Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger

被引:34
作者
Plichta, Jennifer K. [1 ]
Rai, Upahvan [1 ]
Tang, Rong [1 ]
Coopey, Suzanne B. [1 ]
Buckley, Julliette M. [1 ]
Gadd, Michele A. [1 ]
Specht, Michelle C. [1 ]
Hughes, Kevin S. [1 ]
Taghian, Alphonse G. [2 ]
Smith, Barbara L. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
关键词
DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; SURGICAL ADJUVANT BREAST; CONSERVING THERAPY; PREMENOPAUSAL WOMEN; TUMOR RECURRENCE; RISK-FACTORS; STAGE; CHEMOTHERAPY; LESS-THAN-OR-EQUAL-TO-40; RADIOTHERAPY;
D O I
10.1245/s10434-016-5404-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Young age at breast cancer diagnosis has been associated with increased risk of recurrence and mortality. We reevaluated this assumption in a large, modern cohort of women diagnosed with breast cancer at age aecurrency sign40 years. We identified women with breast cancer at age aecurrency sign40 years at a single institution from 1996-2008. We assessed locoregional recurrence (LRR), distant recurrence, disease-free survival (DFS), and overall survival (OS), and correlated patient and tumor characteristics with outcomes. We identified 584 women aged aecurrency sign40 years with breast cancer. Median age was 37 years, and median follow-up was 124 months; 61.5 % were stages 0-I and 38.5 % were stages II-III. Overall, 57.4 % had lumpectomies and 42.5 % mastectomies. DFS was 93 % at 5 years and 84.5 % at 10 years. OS was 93 % at 5 years and 86.5 % at 10 years. On multivariate analysis, worse DFS was associated with positive nodes (p = 0.002); worse OS was associated with larger tumor size (p = 0.042). When stratified by lumpectomy versus mastectomy, there were no significant differences in survival or recurrence. For lumpectomy patients, DFS was 96 % at 5 years and 88 % at 10 years; OS was 96 % at 5 years and 89 % at 10 years. For mastectomy patients, DFS was 89.5 % at 5 years and 79 % at 10 years; OS was 90 % at 5 years and 83 % at 10 years. Lumpectomy LRR rates were 1 % at 5 years and 4 % at 10 years. Mastectomy LRR rates were 3.5 % at 5 years and 8.7 % at 10 years. Outcomes for women with breast cancer at age aecurrency sign40 years have improved. Lumpectomy recurrence rates are low, suggesting that lumpectomy is oncologically safe for young breast cancer patients.
引用
收藏
页码:3212 / 3220
页数:9
相关论文
共 35 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer [J].
Anderson, Stewart J. ;
Wapnir, Irene ;
Dignam, James J. ;
Fisher, Bernard ;
Mamounas, Eleftherios P. ;
Jeong, Jong-Hyeon ;
Geyer, Charles E., Jr. ;
Wickerham, D. Lawrence ;
Costantino, Joseph P. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2466-2473
[3]  
[Anonymous], 2015, Breast Cancer Facts Figures 2015-2016
[4]  
[Anonymous], 2016, J NATL COMPR CANC NE
[5]   Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy [J].
Arvold, Nils D. ;
Taghian, Alphonse G. ;
Niemierko, Andrzej ;
Raad, Rita F. Abi ;
Sreedhara, Meera ;
Nguyen, Paul L. ;
Bellon, Jennifer R. ;
Wong, Julia S. ;
Smith, Barbara L. ;
Harris, Jay R. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (29) :3885-3891
[6]   Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial [J].
Bartelink, Harry ;
Maingon, Philippe ;
Poortmans, Philip ;
Weltens, Caroline ;
Fourquet, Alain ;
Jager, Jos ;
Schinagl, Dominic ;
Oei, Bing ;
Rodenhuis, Carla ;
Horiot, Jean-Claude ;
Struikmans, Henk ;
Van Limbergen, Erik ;
Kirova, Youlia ;
Elkhuizen, Paula ;
Bongartz, Rudolf ;
Miralbell, Raymond ;
Morgan, David ;
Dubois, Jean-Bernard ;
Remouchamps, Vincent ;
Mirimanoff, Rene-Olivier ;
Collette, Sandra ;
Collette, Laurence .
LANCET ONCOLOGY, 2015, 16 (01) :47-56
[7]   TEN-YEAR RECURRENCE RATES IN YOUNG WOMEN WITH BREAST CANCER BY LOCOREGIONAL TREATMENT APPROACH [J].
Beadle, Beth M. ;
Woodward, Wendy A. ;
Tucker, Susan L. ;
Outlaw, Elesyia D. ;
Allen, Pamela K. ;
Oh, Julia L. ;
Strom, Eric A. ;
Perkins, George H. ;
Tereffe, Welela ;
Yu, Tse-Kuan ;
Meric-Bernstam, Funda ;
Litton, Jennifer K. ;
Buchholz, Thomas A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :734-744
[8]   Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[9]   Effect of screening and adjuvant therapy on mortality from breast cancer [J].
Berry, DA ;
Cronin, KA ;
Plevritis, SK ;
Fryback, DG ;
Clarke, L ;
Zelen, M ;
Mandelblatt, JS ;
Yakovlev, AY ;
Habbema, JDF ;
Feuer, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792
[10]   Patient and Tumor Characteristics Associated With Increased Mortality in Young Women (≤40 Years) With Breast Cancer [J].
Bharat, Ankit ;
Aft, Rebecca L. ;
Gao, Feng ;
Margenthaler, Julie A. .
JOURNAL OF SURGICAL ONCOLOGY, 2009, 100 (03) :248-251